Kappos L - Search Results

1

No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.

Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg SJ, You X, Wang P, Giannattasio G. Kappos L, et al. Mult Scler. 2017 Nov;23(13):1736-1747. doi: 10.1177/1352458516683266. Epub 2016 Dec 22. Mult Scler. 2017. PMID: 28080250 Clinical Trial.

2

Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.

Polman CH, Dahlke F, Thompson AJ, Ghazi M, Kappos L, Miltenburger C, Pozilli C. Polman CH, et al. Among authors: kappos l. Mult Scler. 1995;1 Suppl 1:S51-4. Mult Scler. 1995. PMID: 9345400 Clinical Trial.

3

Interferon beta in the treatment of multiple sclerosis--closing remarks.

Kappos L. Kappos L. Mult Scler. 1995;1 Suppl 1:S64-6. Mult Scler. 1995. PMID: 9345403 Review. No abstract available.

4

Combinations of drugs.

Kappos L. Kappos L. Mult Scler. 1996 Jul;1(6):400-3. doi: 10.1177/135245859600100624. Mult Scler. 1996. PMID: 9345426

5

Use of composite scores in the quantification of deterioration in multiple sclerosis.

Lienert C, Lechner-Scott J, Schött D, Constantinescu C, Kappos L. Lienert C, et al. Among authors: kappos l. Mult Scler. 1999 Aug;5(4):220-2. doi: 10.1177/135245859900500405. Mult Scler. 1999. PMID: 10467379 Review. No abstract available.

6

Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis.

Constantinescu CS, Freitag P, Kappos L. Constantinescu CS, et al. Among authors: kappos l. Mult Scler. 2000 Dec;6(6):378-81. doi: 10.1177/135245850000600603. Mult Scler. 2000. PMID: 11212132 Clinical Trial.

7

Can the Expanded Disability Status Scale be assessed by telephone?

Lechner-Scott J, Kappos L, Hofman M, Polman CH, Ronner H, Montalban X, Tintore M, Frontoni M, Buttinelli C, Amato MP, Bartolozzi ML, Versavel M, Dahlke F, Kapp JF, Gibberd R. Lechner-Scott J, et al. Among authors: kappos l. Mult Scler. 2003 Mar;9(2):154-9. doi: 10.1191/1352458503ms884oa. Mult Scler. 2003. PMID: 12708811

8

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.

Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, Jakobs P, Lorenz A; European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group. Polman C, et al. Among authors: kappos l. Mult Scler. 2003 Aug;9(4):342-8. doi: 10.1191/1352458503ms923oa. Mult Scler. 2003. PMID: 12926838 Clinical Trial.

9

Towards a european network for multiple sclerosis trials (ENMST).

Kappos L, Polman C, Thompson AJ, Duda P, Clanet M, Comi G, Hartung HP, Montalban X. Kappos L, et al. Mult Scler. 2003 Dec;9(6):627-9. doi: 10.1191/1352458503ms962xx. Mult Scler. 2003. PMID: 14664478

10

Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis.

Hardmeier M, Wagenpfeil S, Freitag P, Fisher E, Rudick RA, Kooijmans-Coutinho M, Clanet M, Radue EW, Kappos L; European rIFN beta-1a in Relapsing MS Dose Comparison Trial Study Group. Hardmeier M, et al. Among authors: kappos l. Arch Neurol. 2003 Dec;60(12):1736-9. doi: 10.1001/archneur.60.12.1736. Arch Neurol. 2003. PMID: 14676048

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

807 results

Search Page

Filters